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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA) was asked to deliver an opinion on the safety of ‘Hovenia dulcis fruit extract’ as
a novel food (NF) for its use in food supplements. The NF concerns a hot water extract of sliced and
dried fruits and peduncles of Hovenia dulcis Thun. The production process is described in sufficient
detail but contains contradictory information regarding the mixing with another ingredient of the NF.
The NF is comprised of mostly carbohydrates (about 90%), about 2% proteins, 5% moisture, less
than 1% fat and about 2% ash. In addition, the NF contains small amounts of flavonoids such as
dihydromyricetin, myricetin and quercetin. The Panel notes limitations of the data provided from the
batch testing regarding proximate analyses and plant secondary metabolites. Given these limitations,
the Panel considers that the data provided by the applicant do not demonstrate that different batches
produced with the described production process meet the proposed specifications. The target
population is the general adult population excluding pregnant and lactating women and people with a
chronic disease, such as liver malfunction. Limited information was provided on a history of
consumption of Hovenia dulcis fruits and on an extract approved in South Korea. A number of
toxicological studies were performed. However, the study reports did not allow to verify that the test
item was representative of the NF. The same applied to a human study provided by the applicant. The
Panel concludes that the safety of the NF has not been established.
© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
Keywords: Hovenia dulcis, hot water extract, novel food, ingredient, flavonoids
Requestor: European Commission following an application by Hovenia Dulcis AB
Question number: EFSA-Q-2018-00279
Correspondence: nda@efsa.europa.eu
EFSA Journal 2020;18(8):6196www.efsa.europa.eu/efsajournal
Panel members: Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-
Ernst, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri and
Marco Vinceti.
Acknowledgements: The Panel wishes to thank for the preparatory work on this scientific opinion:
Qingqing Sun.
Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies),
Turck D, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Kearney J, Maciuk A, Mangelsdorf I, McArdle
HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Frenzel T,
Heinonen M, Marchelli R, Neuh€auser-Berthold M, Poulsen M, Schlatter JR, van Loveren H, Gelbmann W
and Knutsen HK, 2020. Scientific Opinion on the safety of hot water extract of fruits and peduncles of
Hovenia dulcis as a novel food pursuant to Regulation 1(EU) 2015/2283. EFSA Journal 2020;18
(8):6196, 14 pp. https://doi.org/10.2903/j.efsa.2020.6196
ISSN: 1831-4732
© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,
which permits use and distribution in any medium, provided the original work is properly cited and no
modifications or adaptations are made.
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
Safety of hot water extract of Hovenia dulcis fruits
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2020;18(8):6196
Table of contents
Abstract................................................................................................................................................... 1
1. Introduction................................................................................................................................. 4
1.1. Background and Terms of Reference as provided by the European Commission ................................ 4
2. Data and methodologies ............................................................................................................... 4
2.1. Data............................................................................................................................................ 4
2.2. Methodologies.............................................................................................................................. 5
3. Assessment.................................................................................................................................. 5
3.1. Introduction................................................................................................................................. 5
3.2. Identity of the NF......................................................................................................................... 5
3.3. Production process ....................................................................................................................... 5
3.4. Compositional data....................................................................................................................... 6
3.4.1. Stability ....................................................................................................................................... 8
3.5. Specifications ............................................................................................................................... 8
3.6. History of use of the NF and/or of its source .................................................................................. 9
3.7. Proposed uses and use levels and anticipated intake....................................................................... 10
3.7.1. Target population ......................................................................................................................... 10
3.7.2. Proposed uses and use levels ........................................................................................................ 10
3.7.3. Precautions and restrictions of use ................................................................................................ 10
3.8. Absorption, distribution, metabolism and excretion (ADME) ............................................................. 10
3.9. Nutritional information .................................................................................................................. 11
3.10. Toxicological information............................................................................................................... 11
3.10.1. Human data................................................................................................................................. 11
3.11. Allergenicity ................................................................................................................................. 12
4. Discussion ................................................................................................................................... 12
5. Conclusions.................................................................................................................................. 12
Steps taken by EFSA ................................................................................................................................ 12
References............................................................................................................................................... 13
Abbreviations ........................................................................................................................................... 14
Safety of hot water extract of Hovenia dulcis fruits
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2020;18(8):6196
1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 28 of April 2014, the company Hovenia dulcis AB submitted a request in accordance with Article
4 of the Novel Food Regulation (EU) 258/19971 to place on the market the dried fruit and peduncle
extract of Hovenia dulcis Thunberg (HDFPE), as a novel food (NF) to be used in food supplements.
On 20 July 2017, the competent authority of Germany forwarded to the Commission its initial
assessment report, which came to the conclusion that the NF did not meet the criteria for acceptance
of a NF defined in Article (3)1 of Regulation (EU) 258/1997.
On 14 December 2017, the Commission forwarded the initial assessment report to the other
Member States (MSs).
The concerns of a scientific nature raised in the initial assessment and by other MSs can be
summarised as follows:
• The NF was inadequately characterised.
• Regarding the previous human exposure, the documents did not include any data on actual
quantities consumed.
• The dose proposed and the intake of the NF had not been justified.
• Regarding the toxicological information, none of the reports contained precise information on
the test material. In the study of subchronic toxicity, the applicant did not provide sufficient
information to show that the test material used was representative of the NF.
• The potential allergenicity of the NF had not been well explored. No assessment of the
botanical relationship between Hovenia dulcis fruits and other fruits known to cause allergic
reactions in the European population had been undertaken which would have been a valuable
indicator for potential cross reactivity to the food by allergic consumers.
According to Article 35 (1) of Regulation (EU) 2015/22832, any request for placing a novel food on
the market within the Union submitted to a Member State in accordance with Article 4 of Regulation
(EU) 258/1997 and for which the final decision has not been taken before 1 January 2018 shall be
treated as an application under this Regulation.
In accordance with Article 10 (3) of Regulation (EU) 2015/2283, EFSA shall give its opinion as to
whether the update of the Union List referred to in Article 10 (1) is liable to have an effect on human
health.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application and information
submitted by the applicant following two EFSA requests for supplementary information.
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24693.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application.4 As indicated in this guidance, it is
the duty of the applicant to provide all of the available (proprietary, confidential and published)
1 Regulation (EU) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
2 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/
2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and
of the Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
3 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
4 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M,
Salminen S, Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on
the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/
2283. EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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scientific data, including both data in favour and not in favour to supporting the safety of the proposed
NF.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications and the
principles described in the relevant existing guidance documents from the EFSA Scientific Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risk that might be associated with consumption of the NF under the
proposed conditions of use, and is not an assessment of the efficacy of HDFPE with regard to any
claimed benefit.
3. Assessment
3.1. Introduction
The NF is a hot water extract of dried fruits and peduncles of Hovenia dulcis Thunberg (family:
Rhamnaceae), which is commonly named as Japanese raisin tree, Japanese cherry tree and Chinese
raisin tree. Hovenia dulcis trees originate from China, Korea, Himalaya region and Japan and are
cultivated in China, South America and Tanzania (Hyun et al., 2010). The NF is intended to be used as
an ingredient for food supplements.
The applicant indicated that according to Regulation (EU) 2015/2283 this NF falls under the
following categories:
(iv) ‘foods and food ingredients consisting of or isolated from plants, except for foods and food
ingredients obtained by traditional propagating or breeding practices and having a history of safe use’.
3.2. Identity of the NF
The NF is a hot water extract obtained from the dried fruits and peduncles of Hovenia dulcis
Thunberg.
3.3. Production process
The fruits and peduncles are harvested manually in the wild in China in September and October.
Once the fruits and peduncles are mature, they fall off the tree and the workers collect them by hand.
After collection and sorting, the fruits and peduncles are packed in nylon bags of 25 kg and
transported by ship to South Korea where they are screened for pesticide residues and other
impurities.
Then they are stored frozen until they are sliced and dried in the dark, followed by an addition of
water at a ratio of 1:10 (w/v). According to the applicant, the mixture of the dried slices and water is
kept at a temperature of 110–150°C, preferably 120–125°C, and under a pressure ranging from 1 to 3
atm, optimally 1.5 atm, for 15 min to 48 h. In response to EFSA questioning, this wide range for the
duration of the extraction, the applicant explained that the normal production schedule is between
15 min and 12 h and that due to weekends and holidays the schedule has to be adjusted and the
extraction procedure will be different. After the extraction, the mixture is cooled, filtered and
concentrated by evaporation at room temperature at –1.5 atm to a solid content of 40%. In response
to an EFSA question, the applicant informed that subsequently dextrin or maltodextrin is added at a
ratio of 10:6 [extract:(malto)dextrin] to avoid clotting of the pure dried extract, before the mixture is
spray-dried. The Panel notes discrepant information received from the applicant (i.e. file ‘Reply on
EFSA Risk Assessment 1’ on the production process 4/5/2020 provides a Korean and an English
package label which indicates ‘Dextrin 37.5%’, but the same file included also a copy of a certificate of
analysis on a ‘maltodextrin’ product).
After addition of the dextrin/maltodextrin, the NF is delivered to Sweden in airtight polyethylene
bags for encapsulation and packaging. The initial assessment raised concerns by a Member State
regarding the use of ethanol in the production process, however, the applicant clarified that no ethanol
is used. The applicant provided GMP certificates issued by the South Korean Ministry for Food and
Drug Safety and the Korean Food and Drug Agency (KFDA) for the production of the ingredient and by
L€akemedelsverket (Swedish Medical Products Agency) for the filling of capsules and packaging.
Safety of hot water extract of Hovenia dulcis fruits
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2020;18(8):6196
The Panel notes that no analytical data were provided on whether and to which degree the wide
range of the extraction time (i.e. 15 min to 48 h) may impact the composition of the NF. It is also
unclear whether the HDFPE is mixed with dextrin or maltodextrin. The Panel considers that the
production process of the NF is not sufficiently described.
3.4. Compositional data
According to the application, the NF consists of a spray-dried mixture of 62.5% HDFPE and 37.5%
dextrin or maltodextrin. The NF is comprised of mostly carbohydrates (about 90%), about 2%
proteins, 5% moisture, less than 1% fat and about 2% ash; in addition, the NF contains small
amounts (< 100 ppm) of flavonoids.
The applicant provided compositional information on Hovenia dulcis from the literature: Park et al.
(2015) studied the content of four flavonoids in four batches of an extract obtained from the
manufacturer of the NF with a high-performance liquid chromatographic (HPLC) method. That extract
was produced of dried fruit powder extracted with hot water (100°C for 3 h) at a ratio at 1:40 (w/v).
In addition to the differences of the processing of the raw material (i.e. powder) and the extraction
conditions, also the further processing of the extract (centrifugation to remove insoluble particles) and
the drying method (freeze-drying) differed from the production process of the NF. There is also no
note on an addition of (malto)dextrin in this publication by Park et al. (2015). The results of this batch
testing are provided in Table 1. Dihydromyricetin and taxifolin were the most abundant flavonoids in
that extract.
Park et al. (2015) referred also to, but did not quantify, other components in the seeds or fruits of
Hovenia dulcis, such as hovenodulinol, hovenitins I, II and III, (+)-3,30,50,5,7-pentahydroflavanone,
laricitrin, myricetin, (+)-gallocatechin, dihydrokaempferol, saponin C2, b-daucosterol, hovenidulciosides
A1, A2, B1 and B2, hodulosides I and III and hovenidulcigenin reported by Ding et al. (1997),
ShuZhen et al. (2009), Yoshikawa et al. (1995, 1996, 1997) and Xu et al. (2003). In a letter to the
applicant, EFSA noted scientific literature (Yoshikawa et al., 1996; Murakami et al., 1997) about other
phenolic compounds and saponins present in the seeds and fruits of Hovenia dulcis, some of which
may raise safety concerns at certain concentrations (Heim et al., 2002; Hobbs et al., 2013; Engen
et al., 2015). The applicant did not address these concerns.
The applicant also provided information on other batches produced by the manufacturer of the NF
in 2011 and 2013 and on batches produced in 2019. The certificates of analyses issued by the
manufacturer of the NF for four different batches produced in 2011 and 2013 provided only
information on moisture (ranging from 4.3% to 4.7%), quercetin (5.9–8.9 lg/g) and on some
microbiological and chemical contaminants (Table 2).
Table 1: Contents of flavonoids in four batches of a Hovenia dulcis extract (mg/g) produced
differently to the NF, published by Park et al. (2015) and measured by HPLC
Flavonoids (mg/g)
Batch No.
703 701 0807-5 0807-6
Dihydromyricetin 0.88  0.05 1.19  0.03 1.17  0.03 0.33  0.07
Taxifolin 0.86  0.05 0.15  0.01 0.93  0.02 1.64  0.01
Myricetin 0.17  0.01 0.24  0.01 0.06  0.01 0.04  0.01
Quercetin 0.13  0.01 0.03  0.00 0.04  0.01 0.05  0.01
HPLC: high-performance liquid chromatography.
Table 2: Results from testing of batches produced in 2011 and 2013 provided by the applicant
Parameter
Batch number*
LT111048P LT113028P LT113027P LT113026P
14 November 2011 1 October 2013 30 September 2013 3 September 2013
Moisture (%) 4.7 4.3 4.5 4.7
Quercetin (lg/g) 8.3 8.0 7.5 7.3
Total Aerobic Count
(CFU/g)
5 25 5 5
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Consequently, EFSA asked the applicant to provide more qualitative and quantitative data on the
main constituents/proximate analyses of the NF (i.e. ash, moisture, protein, fat, and carbohydrates,
flavonoids) and batch-to-batch analyses in order to show that these parameters meet the limits of the
proposed specifications of the NF.
In response to this request, the applicant provided certificates of analyses from the manufacturer of
the NF on five batches produced in 2019. The results are provided in Table 3.
Parameter
Batch number*
LT111048P LT113028P LT113027P LT113026P
14 November 2011 1 October 2013 30 September 2013 3 September 2013
Yeast and mould
(CFU/g)
5 5 5 5
Coliforms (CFU/g) Negative Negative Negative Negative
Lead (ppm) 0.10 0.1 0.1 0.1
Mercury (ppm) 0.003 n.d. n.d. n.d.
Arsenic (ppm) 0.07 0.1 0.1 0.1
Cadmium (ppm) 0.01 n.d. n.d. n.d.
CFU: colony forming unit.
*: The date below the batch number is the production date; n.d. not detected.
Table 3: Results of batches produced in 2019 and certified by the manufacturer of the NF
Parameter
Batch number*
LT119027P LT119037P LT119043P LT119044P LT119046P
31 July 2019
23 October
2019
28 November
2019
3 December
2019
26 December
2019
Moisture (%) 5.20 5.20 5.20 5.20 5.20
Protein (%) 2.34 2.34 2.34 2.34 2.34
Fat (%) 0.09 0.09 0.09 0.09 0.09
Carbohydrates (%) 91.40 91.40 91.40 91.40 91.40
Polysaccharides
(mg/g)
185.17 185.17 185.17 185.17 185.17
Ash (%) 1.4 1.4 1.4 1.4 1.4
Sodium (mg/100 g) 20.97 20.97 20.97 20.97 20.97
Quercetin (lg/g) 8.49 7.94 7.94 7.99 8.74
Microbiology
Aerobic counts (CFU) < 1,000/g < 1,000/g < 1,000/g < 1,000/g < 1,000/g
E. coli (per 50 g) n.d. n.d. n.d. n.d. n.d.
Coliforms (CFU/g) n.d. n.d. n.d. n.d. n.d.
Yeast and moulds
(CFU/g)
n.d. n.d. n.d. n.d. n.d.
Heavy metals** (ppm)
Lead 0.111 0.111 0.111 0.111 0.111
Mercury 0.001 0.001 0.001 0.001 0.001
Cadmium 0.001 0.001 0.001 0.001 0.001
Arsenic 0.080 0.080 0.080 0.080 0.080
NF: novel food; CFU: colony forming units.
*: The date below the batch number is the production date.
**: Not a specification parameter.
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The Panel notes that the results of all tested parameters, except for quercetin (ranging from 7.94
to 8.74 lg/g), are identical for all five presented batches produced at different time points in 2019,
which is considered unrealistic.
These five batches produced in 2019 and a sixth batch (LT119045P, production date not specified)
were analysed by an external laboratory for their flavonoid content (Table 4).
The Panel notes that taxifolin could not be detected in these six batches and that the results for
the contents of the other three flavonoids in these batches are up to more than 10-fold lower (for
dihydromyricetin) than the results (presented in Table 1) obtained on an extract produced differently
to the NF and which have been proposed by the applicant for setting specifications for
dihydromyricetin, taxifolin and myricetin. The information from this external laboratory indicated that
the analysed substance was a mixture consisting of 62.5% Hovenia dulcis extract and 32.5% dextrin
vs. ‘37.5%’ as indicated in the production process description in the application and as indicated on a
product labelling provided by the applicant. Thus, it appears that the batches produced and tested in
2019 are not identical to the NF.
Another sample of a ‘Hovenia dulcis extract powder’ (as stated by the applicant) and two samples
of food supplements provided by the manufacturer of the NF (without further information on the
tested material) were analysed by the external laboratories Eurofins and the Korean Health
Supplements Institute. The proximate analyses (moisture, protein, fat, carbohydrates, ash) of these
samples were within the proposed specification limits. Flavonoids were not analysed by these
laboratories.
The Panel notes the concerns described above for the proximate analyses provided by the
certificates of the manufacturer of the NF (i.e. identical figures) and regarding the identity of the
analysed batches produced in 2019. Furthermore, the Panel considers that the NF is not sufficiently
characterised regarding secondary plant metabolites.
3.4.1. Stability
No data regarding the stability of the NF were provided by the applicant.
3.5. Specifications
The specifications of the NF proposed by the applicant are presented in Table 5. They include the
parameters for proximate analyses, flavonoids, heavy metals and microbiological specifications.
Table 4: Flavonoid content of six batches produced by the manufacturer of the NF and certified by
an external laboratory
Flavonoids
(lg/g)
Batch no.
LT119027P
31 July
2019
LT119037P
23 October
2019
LT119043P
28 November
2019
LT119044P
3 December
2019
LT119045P
no date
LT119046P
26 December
2019
Dihydromyricetin n.d. 91.37 67.30 66.02 73.20 42.83
Taxifolin n.d. n.d. n.d. n.d. n.d. n.d.
Myricetin 12.08 36.69 27.96 28.05 30.04 27.35
Quercetin 5.18 3.39 4.64 5.13 4.47 4.46
n.d. not detected; NF: novel food.
Table 5: Specifications of the NF proposed by the applicant
Parameter Specification Analytical method
Typical proximate analyses
Moisture (%) 4–6 *
Protein (%) 1–3 *
Fat (%) < 1 *
Carbohydrates (%) 89–94 *
Sugars (%) 18–21 *
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Given the limitations of the batch testing described in Section 3.4, the Panel considers that the data
provided by the applicant do not demonstrate that different batches produced with the described
production process meet the proposed specifications. It is also noted that the testing of batches
produced in 2019 showed significantly lower contents of dihydromyricetin, taxifolin and myricetin
(Table 4) as compared to the proposed specification limits for these flavonoids (Table 5) which were
based on analyses of an extract, which was produced differently from the NF.
3.6. History of use of the NF and/or of its source
According to the applicant, literature (Bampi et al., 2010; Chau and Wu, 2006; Dieu, 1853;
Eleoterio et al., 2012; Lim, 2013; Martin-Garcia and Diez, 2012) demonstrates that Hovenia dulcis
fruits are a commonly used food in Taiwan, Japan, China and Brazil.
Bampi et al. (2010), who studied the composition of Hovenia dulcis fruits and extracts and flour
made of the fruits, noted that Hovenia dulcis is widely distributed in southern Brazil, but that there
were no literature reports of its use in food products. According to two other references from Brazil,
noted by the applicant, Hovenia dulcis is widespread in south Brazil but not well documented (Eleoterio
et al., 2012) and is considered as an invasive species (Martin-Garcia and Diez, 2012). The applicant
has provided a reference for recipes with Hovenia dulcis fruits published in a Brazilian Blog (Sexta-
Feira, 2008). According to Chau and Wu (2006), fruits and seeds of Hovenia dulcis can be used as a
food ingredient in Taiwan, but not in China. Dieu (1853) noted in his medical and therapeutic
compendium that fruits from Hovenia dulcis were tasting like pears when they are ripe, and that local
Japanese called the tree ‘Siku’.
According to a compendium by Lim (2013) on edible medicinal and non-medicinal plants, the ripe
fruits and fruit peduncles are edible raw or cooked and can be used to make candies and substitutes
for honey and wine; it also has been used as a traditional Chinese medicine for more than 1,000 years
to treat alcohol abuse in China.
The applicant also provided an inventory handbook from the US Department of Agriculture on
‘Perennial Edible Fruits of the Tropics’ which indicates the peduncle of Hovenia dulcis as edible parts
under the list of ‘minor fruits’ of Southeast Asia (USDA, 1987). ‘Minor fruits’ were defined as ‘[citation]
usually not widely distributed. They are often small. They may only grow wild and have little or no
Parameter Specification Analytical method
Ash (%) 1.0–2.5 *
Sodium (mg/100 g) ≤ 70 *
Flavonoids
Quercetin (lg/g) 5.9–8.9 HPLC
Dihydromyricetin (mg/g) 0.33–1.19 HPLC
Taxifolin (mg/g) 0.15–1.64 HPLC
Myricetin (mg/g) 0.04–0.24 HPLC
Microbiological parameters
Total aerobic count (CFU/g) < 5 9 103 *
Yeast and mould (CFU/g) < 30 *
Coliforms (CFU/g) < 10 *
E. coli (CFU/g) < 10 *
Coagulase-positive Staphylococcus (CFU/g) < 10 *
S. aureus (CFU/g) < 10 *
Salmonella (CFU/g) ND/25g *
Heavy metals
Lead (ppm) < 1 *
Mercury (ppm) < 0.1 *
Arsenic (ppm) < 1 *
Cadmium (ppm) < 1 *
*: No methods were proposed in section ‘Specifications’ by the applicant, CFU: colony forming unit, ND: not detected; HPLC:
high-performance liquid chromatography; NF: novel food.
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potential for cultivation and marketing. Most probably merit neglect, but some may have the potential
to be improved and developed into a major fruit’.
The dossier contains a scientific article on dietary supplement use by South Korean adults based on
data from the National Complementary and Alternative Medicine Use Survey in 2006 (Ock et al., 2010).
According to this article, 5.2% of South Korean adults had consumed food supplements with ‘Hovenia
dulcis’ in 2006. There was no information, however, in this article about the dose or duration of the
intake or any other specific information on the consumption pattern or on the consumed supplements.
According to the applicant, Hovenia dulcis has been permitted for food use by the KFDA. The
applicant also stated that Hovenia dulcis fruits and peduncles are consumed also as a fresh or dried
fruit in Korea at an estimated quantity of 200,000 kg/year (no reference provided). The dossier also
contains a table presenting 11 food products (eight beverages and three food supplements) from
different companies with ‘Hovenia dulcis extracts’ on the market in South Korea (Table 6). According to
the applicant, a product similar to the NF is already on the market in South Korea.
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The applicant intends to target the general adult population.
3.7.2. Proposed uses and use levels
The applicant intends to use the NF as an ingredient in food supplements in capsule or tablet form
taken up to 6 times a day and with a maximum daily intake of 2.5 g.
3.7.3. Precautions and restrictions of use
According to the applicant, the NF is not recommended for children, pregnant women and
individuals with chronic diseases such as liver malfunction. Following a request by EFSA to provide the
rationale for these restrictions of use, the applicant indicated that no studies have been performed on
pregnant women and children and that recommendations of the Swedish Food Administration
regarding food supplements were followed.
3.8. Absorption, distribution, metabolism and excretion
No studies on the absorption, distribution, metabolism and excretion (ADME) of the NF or any
constituent thereof were provided by the applicant. The applicant argued that the macronutrients of
the NF are expected to be digested according to the usual digestion and absorption routes.
Table 6: Hovenia dulcis extract products on the market in South Korea in 2013
Type of Product Country Daily Dose
Yearly Total
Consumption USD
Volume in Units
Beverage Korea 140 mL (2,460 mg) 80,000,000 40,000,000 bottles
Beverage Korea 100 mL (2,460 mg) 2,400,000 600,000 bottles
Tablet Korea 2,460 mg/Tablet 60,000,000 600,000 boxes
Capsule Korea 2,460 mg/Capsule 250,000 5,000 boxes
Tablet Korea 2,460 mg/Tablet 360,000 6,000 boxes
Beverage Korea 100 mL (1,000 mg) 24,000,000 6,000,000 bottles
Beverage Korea 100 mL 75,000,000 18,750,000 bottles
Beverage (Tea Drinks) Korea 350 mL or 500 mL 40,000,000 20,000,000 bottles
Beverage (Tea Drinks) Korea 350 mL or 500 mL 25,000,000 16,600,000 bottles
Beverage (Tea Drinks) Korea 500 mL 7,000,000 3,880,000 bottles
Beverage (Tea Drinks) Korea 500 mL 5,000,000 2,500,000 bottles
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3.9. Nutritional information
Considering the compositional data as provided by the applicant and as presented in Section 3.4
(Composition) and the maximum daily intake per day of 2.5 g, the Panel considers that consumption
of the NF is not nutritionally disadvantageous.
3.10. Toxicological information
The applicant has provided an acute toxicity study in rats (Biotoxtech, 2002a), a bacterial reverse
mutation test (Biotoxtech, 2002b; unpublished), an in vivo micronucleus test in mice (Biotoxtech,
2002c; unpublished), a chromosome aberration test with hamster lung cells (Biotoxtech, 2002d;
unpublished) and a 90-day subchronic rat study, (Biotoxtech, 2003; unpublished). According to the
applicant, these studies followed KFDA Guidelines for Good Laboratory Practice (GLP). The study
reports of these toxicological tests indicate that ‘Hovenia Dulcis Fruit Extracts’ was the test substance
and describe it as a ‘dark brown powder’, but they also indicated that ‘[citation] other information such
as identity, strength, purity and stability was not provided’.
In two letters to the applicant, EFSA expressed concerns on the genotoxicity testing strategy
applied by the applicant and on the representativeness of the material tested in the toxicological
studies. In order to address these concerns, EFSA asked the applicant to provide an in vitro
mammalian cell micronucleus test performed in accordance to OECD TG 487 and in line with the tiered
genotoxicity testing strategy as indicated by the EFSA Scientific Committee (2011) and by the EFSA
NDA Panel (2016), and an in vitro mammalian cell gene mutation test performed in accordance to
OECD TG 476. EFSA suggested to the applicant to consider the EFSA Scientific Committee Statement
(2019) on genotoxicity assessment of chemical mixtures in particular chapter 2.1.1 (‘Mixtures
containing a substantial fraction of unidentified components’) and chapter 2.3 (‘Genotoxicity
assessment of mixtures containing a substantial fraction of unidentified components’) for these two
requested tests.
Regarding the provided toxicological studies, EFSA asked the applicant to provide information on
the test substance in order to demonstrate that it met the compositional characteristics and
specification limits of the NF. EFSA also noted to the applicant the OECD GLP Guidance requirement
that evaluations of chemicals should be based on safety test data of sufficient quality, rigour and
reproducibility (OECD, 1998). According to the OECD Guidance documents 487 (OECD, 2016) and 408
(OECD, 2018), study reports should include comprehensive qualitative and quantitative
physicochemical information on the identity and characterisation of the test item.
In his response, the applicant provided a letter signed by the chief executive officer (dated 25/10/2017)
which stated that ‘[citation] This is to confirm that the Hovenia Dulcis Extract substance used in the
application for a Novel Food application to EFSA, submitted by Hovenia Dulcis AB, Sweden is the same as in
the KFDA application for an approval for food supplements referred to in the submitted documents. The
substance has also been used in the toxicological studies performed by Biotoxtech Inc. which are reported
in the application’. However, no data regarding the compositional characteristics and specification
parameters of the material tested in the toxicological studies were provided by the applicant.
The Panel notes that the letter provided by the applicant does not allow EFSA to validate that the
identity of the test substance and its physicochemical composition are representative for the NF.
Consequently, the Panel considers that the provided toxicological study reports are not informative for
the assessment of the toxicological properties of the NF.
3.10.1. Human data
Two human studies in adults and a report on a paediatric case of toxic hepatitis associated with the
consumption of products obtained from Hovenia dulcis were provided.
An unpublished report summarised a double-blinded, placebo-controlled trial with 74 subjects aged
18–70 years with alcohol-induced liver damage (inclusion criterion: c-glutamyl transpeptidase (c-GTP)
≥ 60) who either received three times per day 900 mg of a ‘Hovenia dulcis berry extract powder’
produced by the manufacturer of the NF or placebo for 12 weeks (Lifetree Biotech, undated). The trial
was conducted in 2007–2008. The Panel notes that the study report did not provide information (e.g.
certificate of analysis, any compositional characteristic of the NF) which would allow to verify that the
test item was representative for the NF. The Panel considers therefore that this human study is not
informative for the assessment of the safety of the NF.
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The second human study used a hot water extract of Hovenia dulcis fruits (boiled for 4 h) produced
by the manufacturer of the NF which met the specifications for quercetin of the NF (i.e. 5.9–8.9 lg/g)
(Kim et al., 2017). It was a randomised controlled crossover trial with 26 male adults with a mean age
of 24 years who received a single dose of 2.5 g of the NF together with 360 mL of Korean Soju
(17.5% v/v alcohol) in order to evaluate effects of the NF on ‘hang over’ symptoms. The Panel notes
the limitations of this study for its use to assess the safety of the NF (i.e. single dose, low number of
subjects, co-consumption with alcohol and the study objective) and considers that this study is not
relevant for the safety assessment of the NF.
The case report concerned a 3.6-year-old boy who had consumed water boiled with Hovenia dulcis
daily (plant part not specified) for about a year prior to the diagnosis of a severe toxic hepatitis and
was evaluated for liver transplantation (Kim et al., 2012). There was no further information about the
amount of beverage ingested, the concentration of Hovenia dulcis fruits in the beverage. According to
the authors, the case was classified ‘probable’ causally related to the consumption of Hovenia dulcis.
The Panel notes that case reports per se are not suitable to establish a cause and effect relationship.
There is no information available on how the consumed item relates with the composition and
proposed intake level of the NF, thus the relevance of this paediatric case remains unclear.
3.11. Allergenicity
According to the proposed specifications, the NF contains 1–3% protein. According to the applicant,
there are no reports on allergic reactions associated with Hovenia dulcis fruits although more than 750
million ‘products’ of Hovenia dulcis fruit extract have been consumed since the substance was
approved by the KFDA in 2008. The applicant also noted that he could not identify reports concerning
allergenicity from China, Japan and Brazil where the fruit is consumed.
4. Discussion
The NF concerns a hot water extract from the ripe fruits and peduncles of Hovenia dulcis Thunb.
collected from the wild in China. The Panel considers that the proposed specifications are not
supported by an appropriate compositional characterisation and by batch testing.
The applicant has provided some information on a history of consumption of Hovenia dulcis fruits
and extracts in foods, mainly beverages and food supplements, and in the traditional Chinese medicine
in countries in South Asia.
The application includes study reports on an acute toxicity study, a bacterial reverse mutation test,
an in vivo micronucleus test, a chromosome aberration test and a 90-day subchronic toxicity study in
rats. The genotoxicity studies provided by the applicant do not comply with EFSA Guidance
documents, as an in vitro micronucleus test is missing. In addition, the studies provided did not
include information that permitted the identification and characterization of the test substance.
Consequently, the Panel considers that the provided toxicological study reports are not informative
for the assessment of the toxicological properties of the NF and cannot be used to derive safe intake
levels for human consumption. Similarly, an unpublished study report on a human trial for 12 weeks
did not provide information which would allow to verify that the test item was representative for the
NF. Another human trial concerning the effect of a single dose of 2.5 g of the NF on hang-over
symptoms is considered not relevant for the safety assessment of the NF.
5. Conclusions
The Panel concludes that the safety of the NF has not been established.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of Hovenia dulcis fruit extract as a novel food
Ref. ARES(2018)5373981 dated 19.10.2018.
2) On 19.10.2018, EFSA received a valid application from the European Commission on Hovenia
dulcis fruit extract as a novel food, which was submitted by Hovenia dulcis AB, and the
scientific evaluation procedure started.
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3) On 18.01.2019, 08.03.2019, 11.03.2019 and 29.05.2019 EFSA requested the applicant to
provide additional information to accompany the application and the scientific evaluation was
suspended.
4) On 07.03.2019, 11.03.2019, 12.03.2019 and 04.05.2020 additional information was provided
by the applicant and the scientific evaluation was restarted.
5) During its meeting on 30.06.2020, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of Hovenia dulcis fruit extract as a novel food pursuant to
Regulation (EU) 2015/2283.
References
Bampi M, Bicudo MOP, Fontoura PSG and Ribani RK, 2010. Chemical composition of fruit, concentrated extract and
flour from “Japanese grape”. Ciencia Rural, 40, 2361–2367.
Biotoxtech, 2002a. Hovenia Dulcis Fruit Extracts; single dose toxicity study (oral) in rats (study number: B02063).
Unpublished report.
Biotoxtech, 2002b. Hovenia Dulcis Fruit Extracts; In vitro Reverse Mutation study. (study number: B02064).
Unpublished report.
Biotoxtech, 2002c. Hovenia Dulcis Fruit Extracts; Micronucleus test in Mice. (study number: B02066). Unpublished
report.
Biotoxtech, 2002d. Hovenia Dulcis Fruit Extracts; In vitro Chromosomal Aberration study using Chinese Hamster
Lung (CHL) Cultured cell (study number: B02065). Unpublished report.
Biotoxtech, 2003. Hovenia Dulcis Fruit Extracts; 13 week repeated dose toxicity study (oral) with 4 week recovery
period in Rats (study number: B02067). Unpublished report.
Chau CF and Wu SH, 2006. The development of regulations of Chinese herbal medicines for both medicinal and
food uses. Trends in Food Science & Technology, 17, 313–323.
Dieu S, 1853. Traite de matiere medicale et de therapeutique, precede de considerations generales sur la zoologie
et suivi de l’histoire des eaux naturelles. Volumen 4, Paris, Pallez et Rousseau, libraires-editeurs.
Ding L, Liang Q and Teng Y, 1997. Study on flavonoids in seeds of Hovenia dulcis. Yao Xue Xue Bao, 32, 600–602.
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016. Guidance on the preparation and
presentation of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283.
EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
EFSA Scientific Committee, 2011. Scientific Opinion on genotoxicity testing strategies applicable to food and feed
safety assessment. EFSA Journal 2011;9(9):2379, 69 pp. https://doi.org/10.2903/j.efsa.2011.2379. Available
online: www.efsa.europa.eu/efsajournal
EFSA Scientific Committee, More S, Bampidis V, Benford D, Boesten J, Bragard C, Halldorsson T, Hernandez-Jerez
A, Hougaard-Bennekou S, Koutsoumanis K, Naegeli H, Nielsen SS, Schrenk D, Silano V, Turck D, Younes M,
Aquilina G, Crebelli R, Gurtler R, Hirsch-Ernst KI, Mosesso P, Nielsen E, Solecki R, Carfı M, Martino C, Maurici D,
Parra Morte J and Schlatter J, 2019. Statement on the genotoxicity assessment of chemical mixtures. EFSA
Journal 2019;17(1):5519, 11 pp. https://doi.org/10.2903/j.efsa.2019.5519
Eleoterio J, Pellens G and Commanduli MJ, 2012. Diameter, height and volume growth of hovenia dulcis in south
blumenau, sc. 42, 733–740.
Engen A, Maeda J, Wozniak DE, Brents CA, Bell JJ, Uesaka M, Aizawa Y and Kato TA, 2015. Induction of
cytotoxicity and genotoxicity responses by natural and novel quercetin glycosides. Mutation Research, 2015,
15–22.
Heim KE, Tagliaferro AR and Bobilya DJ, 2002. Flavonoid antioxidants: chemistry, metabolism and structure-activity
relationships. Journal of Nutrional Biochemistry, 13, 572–584.
Hobbs CA, Swartz C, Maronpot R, Davis J, Recio L, Koyanagi M and Hayashi S, 2013. Genotoxicity evaluation of
the flavonoid, myricitrin, and its aglycone, myricetin. Food and Chemistry Toxicology, 83, 283–292.
Hyun TK, Eom SH, Yu CY and Roitsch T, 2010. Hovenia dulcis – an Asian traditional herb. Planta Medicine, 76,
943–949. https://doi.org/10.1055/s-0030-1249776
Kim YJ, Ryu SL, Shim JW, Kim DS, Shim JY, Park MS and Jung HL, 2012. A pediatric case of toxic hepatitis induced
by Hovenia dulcis. Pediatric Gastroenterology, Hepatology and Nutrition Journal, 15, 111–116.
Kim H, Kim YJ, Jeong HJ, Kim JY, Choi EK, Chae SW and Kwon O, 2017. A Standardized extract of the fruit of
Hovenia Dulcis alleviated alcohol-induced hangover in healthy subjects with heterozygous ALDH2: a and
omized crossover, crossover trial. Journal of Ethnopharmacology, 209, 167–174.
Lifetree Biotech Co., undated. An Evaluation of Efficacy of Hovenia dulcis Berry extract powder to Repair Alcohol-
Induced Liver Damage in Double Blind, Randomization, Controlled Clinical Trials. Unpublished report.
Lim TK, 2013. Hovenia dulcis. Edible Medicinal And Non-Medicinal Plants. ISBN 978-94-007-5653-3 Volumen 5,
Fruits. Springer Netherlands, 568–577.
Martin-Garcia Y and Diez JJ, 2012. Sustainable Forest Management: Case studies. Rijeka, Croatia, Intech.
Safety of hot water extract of Hovenia dulcis fruits
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2020;18(8):6196
Murakami N, Ueda T, Yoshikawa M, Matsuda H, Yamahara J, Saito M and Tanaka T, 1997. Histamine release
inhibitory and alcohol induced muscle relaxation inhibitory constituents from Hoveniae semen Seu Fructus.
Absolute structure of methyl-migrated 16,17-seco-dammarane triterpene glycosides, hovenidulciosides. Tennen
Yuki Kagobutsu Toronkai Koen Yoshishu, 1995, 37th, 397.
Ock SM, Hwang SS, Lee JS, Song CH and Ock CM, 2010. Dietary supplement use by South Korean adults: data
from the national complementary and alternative medicine use survey (NCAMUS) in 2006. Nutritional Research
Practice, 4, 69–74. https://doi.org/10.4162/nrp.2010.4.1.69
OECD, 1998. OECD Principles on Good Laboratory Practice, OECD Series on Principles of Good Laboratory Practice
and Compliance Monitoring. Vol No. 1. OECD Publishing, Paris. https://doi.org/10.1787/9789264078536-en
OECD, 2016. Test No. 487: In Vitro Mammalian Cell Micronucleus Test, OECD Guidelines for the Testing of
Chemicals, Section 4, OECD Publishing, Paris. https://doi.org/10.1787/9789264264861-en
OECD, 2018. Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents, OECD Guidelines for the Testing
of Chemicals, Section 4, OECD Publishing, Paris. https://doi.org/10.1787/9789264070707-en
Park JS, Kim IS, Rehman Shaheed Ur, Na CS and Yoo HH, 2015. HPLC determination of bioactive flavonoids in
hovenia dulcis fruit extracts. Journal of Chromatographic Science, 54, https://doi.org/10.1093/chromsci/
bmv114
Sexta-Feira, 2008. E tempo de uva japonesa. Available online: https://come-se.blogspot.com/2008/05/tempo-de-
uva-japonesa.html
ShuZhen Y and QiuSheng F, 2009. The nootropic components of Hovenia dulcis. Academic Journal of Second
Military Medical University, 30, 1281–1287.
USDA, 1987. Perennial Edible Fruits of the Tropics: An. Inventory. U.S. Department of Agriculture,. Agriculture
Handbook No. 642, 252 pp. https://naldc.nal.usda.gov/download/CAT87886130/PDF
Xu BJ, Lee JH and Sung CK, 2003. Review: chemical compositions of the genus Hovenia. Natural Product Sciences,
9, 143–153.
Yoshikawa M, Ueda T, Muraoka O, Aoyama H, Matsuda H, Shimoda H, Yamahara J and Murakami N, 1995.
Absolute stereostructures of hovenidulciosides A1 and A2, bioactive novel triterpene glycosides from hoveniae
semen seu fructus, the seeds and fruit of Hovenia dulcis Thunb. Chemical and Pharmaceutical Bulletin, 43,
532–534.
Yoshikawa M, Murakami T, Ueda T, Matsuda H, Yamahara J and Murakami N, 1996. Bioactive saponins and
glycosides. IV. Four methylmigrated 16,17-seco-dammarane triterpene gylcosides from Chinese natural
medicine, hoveniae semen seu fructus, the seeds and fruit of Hovenia dulcis Thunb, absolute stereostructures
and inhibitory activity on histamine release of hovenidulciosides A1, A2, B1, and B2. Chemical &
Pharmaceutical Bulletin, 44, 1736–1743.
Yoshikawa M, Murakami T, Ueda T, Yoshizumi S, Ninomiya K, Murakami N, Matsuda H, Saito M, Fujii W, Tanaka T
and Yamahara J, 1997. Bioactive constituents of Chinese natural medicines. III. Absolute stereostructures of
new dihydroflavonols, hovenitins I, II, and III, isolated from hoveniae semen seu fructus, the seed and fruit of
Hovenia dulcis THUNB. (Rhamnaceae): inhibitory effect on alcohol-induced muscular relaxation and
hepatoprotective activity. Yakugaku Zasshi, 117, 108–118.
Abbreviations
ADME absorption, distribution, metabolism and excretion
CFU colony forming unit
GLP good laboratory practice
GMP Good Manufacturing Practices
HDFPE Hovenia dulcis fruit and peduncle extract
HPLC high-performance liquid chromatography
ICP-MS induced coupled plasma-mass spectrometry
KFDA Korean Food and Drug Agency
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